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SloveniaPrevaccination genomic diversity of human papillomavirus genotype 6 (HPV 6) was established by
sequencing 3798 bp of 77 clinically important HPV 6 isolates obtained from 45 and 32 patients with genital
warts and laryngeal papillomas, respectively. By analyzing pooled L1, LCR, E6, E2, and E5 nucleotide data of an
individual isolate, a total of 36 different genomic variants were identiﬁed, of which six (12 isolates), one (one
isolate) and 29 (64 isolates) corresponded to HPV 6b, HPV 6a, and HPV 6vc genetic lineages, respectively.
Several novel, potentially important mutations were identiﬁed. Non-prototypic HPV 6vc genomic variants
were found in the majority of genital warts and laryngeal papillomas included in the study. The presence of
serious HPV 6 genome sequence errors was conﬁrmed and novel sequence errors were identiﬁed in sequence
repositories.
© 2009 Elsevier Inc. All rights reserved.Introduction
Human papillomavirus genotype 6 (HPV 6) is one of the most
important HPV genotypes. Next to HPV 11, it is the major causative
agent of genital warts and laryngeal papillomas, the most frequent
benign tumours in the anogenital region and lower respiratory tract,
respectively (Gissmann et al., 1983; Gale et al., 1994; Brown et al.,
1999; Gale, 2005; Gale and Zidar, 2006; Potočnik et al., 2007).
According to the latest papillomavirus classiﬁcation criteria, HPV 6 is
placed in the alpha genus— species 10, together with HPV 11, HPV 13,
HPV 44, and HPV 74 (de Villiers et al., 2004). Based on its clinical
association mainly with benign lesions, HPV 6 is regarded as a “low-
risk” HPV genotype (reviewed in Grassmann et al. (1996)). HPV 6 is
one of the four primary targets of the recently introduced quad-
rivalent HPV vaccine (Barr and Tamms, 2007; Garland et al., 2007).
HPV 6 was discovered by Southern blot hybridization in a tissue
specimen of condyloma acuminata (Gissmann and zur Hausen, 1980).
The complete genome, later designated HPV 6b, was cloned in 1981
(de Villiers et al., 1981) and fully sequenced and completely
characterized two years later (Schwarz et al., 1983). Molecular studies
performed in the years following the discovery of this virus
demonstrated that HPV 6 is polymorphic and consists of severalll rights reserved.genomic variants. The focus of these studies has been on certain
portions of the HPV 6 genome, particularly the long-control region
(LCR), which contains regulatory elements for viral transcription and
replication, and the coding regions for L1, L2, E6, E7, and E2 proteins
(Rando et al., 1986; Kasher and Roman,1988; Farr et al., 1991; Icenogle
et al., 1991; Yaegashi et al., 1993; Kitasato et al., 1994; Heinzel et al.,
1995; Roman and Brown, 1995; Grassmann et al., 1996; Suzuki et al.,
1997; Caparros-Wanderley et al., 1999; Kovelman et al., 1999). In
addition to HPV 6b, complete genomes of two closely related HPV 6
isolates, designated HPV 6a and HPV 6vc, have been cloned and fully
characterized (Hofmann et al., 1995; Kovelman et al., 1999). On the
basis of nucleotide sequence comparisons, HPV 6 isolates are usually
grouped into prototype HPV 6b-related (prototypic) and HPV 6a/6vc-
related (non-prototypic) genomic variants (Heinzel et al., 1995;
Grassmann et al., 1996; Caparros-Wanderley et al., 1999; Kovelman
et al., 1999). Non-prototypic HPV 6 genomic variants seem to
predominate in genital warts (Gissmann et al., 1983; Rubben et al.,
1992; Brown et al., 1993; Krige et al., 1997; Suzuki et al., 1997;
Caparros-Wanderley et al., 1999).
Knowledge about the natural genetic diversity of HPV 6 is fairly
limited, since the majority of HPV 6 genomic diversity studies
performed so far have only investigated a limited number of isolates,
which were almost exclusively from genital warts, and studies have
focused on a single HPV 6 genomic region or even its short part only.
Thus, in the present study we further investigated genomic diversity
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for future epidemiological, functional and molecular assay develop-
ment and vaccination studies. To achieve this, approximately half of
the genome (3798 bp) of 77 clinically important HPV 6 isolates (e.g.,
those causing disease) was sequenced. The nucleotide sequence
alignments were used to identify HPV 6 genomic variants and to
investigate the linkage of these variants across the L1, LCR, E6, E2, E5a
and E5b genomic regions. In addition, the coding regions were
examined in detail to determine the prevalence, extent and distribu-
tion of amino acid changes that might have important biological
properties. The LCR genomic region was used to determine the
relationship between genomic variants described in our study and
those described previously (Heinzel et al., 1995). This study, carried
out on the largest number of HPV 6 isolates to date, is believed to be
the ﬁrst extensivework on the genetic diversity of the HPV 6 genotype.
Results
All 77 HPV 6 isolates included in the study were successfully
ampliﬁed and sequenced across the L1 (nt 5700–7495), LCR-E6
(nt 7233–650) and E2–E5 (nt 3142–4538) genomic regions. Genomic
sequences were established for 541 bp of E2 ORF (nt 3289–3829), for
the entire LCR genomic region and for the entire L1, E6, E5a, and E5b
ORFs. HPV 6 L1, E6, E2 and E5 genomic variants were identiﬁed using
the prototype HPV 6b genome (GenBank accession no. X00203) as a
standard for comparison and nucleotide position numbering. For the
determination of HPV 6 LCR genomic variants, an LCR sequence
amended by inclusion of a 94 bp segment at position 7350 in the
prototype HPV 6b genome (Heinzel et al., 1995) was used.
HPV 6 L1 genomic variants
A total of ﬁfteen L1 genomic variants were identiﬁed among 77
HPV 6 isolates (Fig. 1). Prototypic and non-prototypic HPV 6 genomic
variants were determined in 12/77 (15.6%) and in 65/77 (84.4%)
isolates, respectively. The prototype L1 sequencewas identiﬁed in only
6/77 (7.8%) isolates. Sequence analysis of the entire L1 gene revealed
25 nucleotide exchanges between the variants and the prototype HPV
6 sequence. The maximum distance between the variants and the
prototype sequence was 11 nucleotides (0.7% of the entire L1 ORF).
Nucleotide substitutions altered the L1 amino acid sequence of one
prototypic (6-L1-3, represented by two isolates) and two non-
prototypic (6-L1-13 and 6-L1-14, represented by ten and one isolate,
respectively) HPV 6 variants; up to two amino acids (0.4% of the L1
protein) were exchanged (Fig. 1).
HPV 6 LCR genomic variants
A total of ﬁfteen LCR genomic variants were identiﬁed among 77
HPV 6 isolates (Fig. 1). Prototypic and non-prototypic HPV 6 genomic
variants were determined in 12/77 (15.6%) and in 65/77 (84.4%)
isolates, respectively. None of the isolates corresponded to the
prototype LCR sequence. Mutations were observed in 39 genomic
positions: 30 single nucleotide exchanges, one 6 bp and one 1 bp
deletion, and two 20 bp, one 14 bp and one 1 bp insertions. The
maximum genomic distance between the variants and the prototype
sequence was 20 mutations, thereby affecting 2.5% (20/806) of the
entire LCR genomic region.
HPV 6 E6 genomic variants
A total of ten E6 genomic variants were identiﬁed among 77 HPV 6
isolates (Fig. 1). Prototypic and non-prototypic HPV 6 genomic
variants were determined in 12/77 (15.6%) and in 65/77 (84.4%)
isolates, respectively. None of the isolates corresponded to the
reference E6 sequence. Molecular analysis of the entire E6 ORFrevealed 13 point mutations observed in 12 genomic positions. The
maximum distance between the variants and the prototype sequence
was 7 nucleotides (1.5% of the entire E6 gene). Nucleotide substitu-
tions altered the E6 amino acid sequence of all non-prototypic HPV 6
variants (65 isolates); up to two amino acids (1.3% of the E6 protein)
were exchanged (Fig. 1).
HPV 6 E2 genomic variants
A total of nine E2 genomic variantswere identiﬁed among77HPV-6
isolates (Fig. 2). Prototypic andnon-prototypicHPV6 genomic variants
were determined in 12/77 (15.6%) and in 65/77 (84.4%) isolates,
respectively. The reference E2 sequence was identiﬁed in 9/77 (11.8%)
isolates. Sequence analysis of the 541bp segmentof E2ORF revealed 23
nucleotide exchanges between the variants and the prototype E2
sequence. The maximum variant divergence from the prototype
sequence was 16 nucleotides, thereby affecting 2.9% of the evaluated
E2 nucleotide sequence. Point mutations altered the E2 amino acid
sequence of one prototypic (6-E2-2, represented by one isolate) and all
non-prototypic (65 isolates)HPV6 variants. As shown in Fig. 2, up to 10
amino acids (5.6% of the analyzed part of the E2 protein) were
exchanged.
HPV 6 E5a and E5b genomic variants
A total of sixteen E5a genomic variants were identiﬁed among 77
HPV 6 isolates (Fig. 2). Prototypic and non-prototypic HPV 6 genomic
variants were determined in 12/77 (15.6%) and in 65/77 (84.4%)
isolates, respectively. The reference E5a sequence was identiﬁed in
12/77 (15.6%) isolates. There were 22 point mutations observed in 19
genomic positions. The maximum genomic distance between the
variants and the prototype sequencewas 14 nucleotides, amounting to
a diversity of 5.1% of the entire E5a ORF. Nucleotide substitutions
altered the E5a amino acid sequence of all non-prototypic HPV 6
variants (65 isolates); up to seven amino acids (7.7% of the E5a
protein) were exchanged (Fig. 2).
A total of nine E5b genomic variants were identiﬁed among 77 HPV
6 isolates (Fig. 2). Prototypic and non-prototypic HPV 6 genomic
variants were determined in 12/77 (15.6%) and in 65/77 (84.4%)
isolates, respectively. The prototype E5b sequence was identiﬁed in
10/77 (13.0%) isolates. Sixteen point mutations were observed in 15
positions. The maximum distance between the variants and the
prototype sequence was 11 nucleotides, thereby affecting 5.0% of the
entire E5b ORF. Point mutations altered the E5b amino acid sequence
of all non-prototypic HPV 6 variants (65 isolates)— up to seven amino
acids (9.7% of the E5b protein) were exchanged (Fig. 2).
HPV 6 genomic variants
The nucleotide data of L1, LCR, E6, E2, and E5 genomic regions were
combined in individual isolates and HPV 6 genomic variants were
determined. Thus, among 77 HPV 6 analyzed isolates, 36 different
genomic variants were identiﬁed (Fig. 3). As shown in Fig. 3, strong
intergenomic co-variation between LCR, late (L1), and early (E6, E2,
E5a, and E5b) viral genes was observed in all analyzed isolates.
Twelve (15.6%) HPV 6 isolates represented genomic variants of the
prototype HPV 6 isolate (six genomic variants) while 65 (84.4%)
isolates represented closely related genomic variants of HPV 6a (one
genomic variant, represented by one isolate) and HPV 6vc (29
genomic variants) (Fig. 3).
Distribution of HPV 6 genomic variants in genital warts vs. laryngeal
papillomas
A total of 22 different HPV 6 genomic variants were identiﬁed
among 45HPV 6 isolates from genital warts. Prototypic HPV 6 genomic
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genomic variants in 41/45 (91.1%) isolates. Similarly, a total of 20
different HPV 6 genomic variants were identiﬁed among 32 HPV 6
isolates from laryngeal papillomas. Prototypic and non-prototypic
HPV 6 genomic variants were determined in 8/32 (25.0%) and in
24/32 (75.0%) isolates, respectively. The difference in the prevalence
of prototypic vs. non-prototypic variants in genital warts and
laryngeal papillomas, calculated by the two-tailed Chi-square test
(SPSS for Windows v15.0.0.0), did not reach statistical signiﬁcance
(P=.1091).
LCR sequences of HPV 6 isolates vs. LCR sequences of HPV 6b, HPV 6a,
and HPV 6vc
All 77 HPV 6 isolates included in the study, classiﬁed as HPV 6b,
HPV 6a or HPV 6vc genomic variants, contained a 94 bp segment (D1),
which is still missing after genomic position 7350 in the prototype
HPV 6b genome in available sequence repositories (GenBank acc. no.
X00203) (Fig. 4). In addition, none of the HPV 6 isolates corresponded
to the corrected version of this sequence (Heinzel et al., 1995). The LCR
sequence of a single HPV 6a-related isolate identiﬁed in this study
fully matched the LCR sequence of HPV 6a (GenBank acc. no. L41216).
In contrast, none of the 65 HPV 6vc-related isolates was identical to
the LCR sequence of HPV 6vc (GenBank acc. no. AF092932). As shown
in Fig. 4, all isolates, including the HPV 6b- and HPV 6a-related
isolates, contained a 19 bp segment (D2), which is missing after
genomic position 7367 in the HPV 6vc genome sequence in available
sequence repositories.
Phylogenetic analysis
Phylogenetic analysis of a 264–268 bp segment of the LCR genomic
region of (i) 77 Slovenian HPV 6 isolates, (ii) the prototype HPV 6b
sequence, (iii) the HPV 6a and HPV 6vc reference isolates and (iv) 31
isolates of HPV 6 originating from 7 different geographic regions
(Brazil, Germany, India, Italy, Japan, USA-NY, and Senegal), revealed a
phylogenetic tree with two dichotomically separated clusters (Fig. 5).
As shown in Fig. 5, one cluster (P) contained the prototype HPV 6b
and 24 related HPV 6 isolates, which represented six separated
variant sub-clusters (P1–P6). The second cluster (N) contained HPV
6a and HPV 6vc, and 83 related HPV 6 isolates, which represented
13 distinct variant sub-clusters (N1–N13). The HPV 6 isolate SN6-1
(sub-cluster In), which is positioned between clusters P and N, can
be considered to be an intermediate genome between the proto-
typic and non-prototypic HPV 6 genomic variants (Heinzel et al.,
1995). Of the 12 Slovenian HPV 6 isolates that grouped to cluster P,
six were identical to the HPV 6 isolate from Germany (sub-cluster
P1), four to HPV 6 isolates from Brazil, India and USA (sub-cluster
P5), and two isolates were identical to the HPV 6 isolate from USA
(sub-cluster P4). Of the 65 Slovenian HPV 6 isolates from cluster N,
52 grouped together with HPV 6 isolates from Brazil, Germany, Italy,
Japan and Senegal (sub-cluster N1), 10 with HPV 6 isolates from
Germany and Senegal (sub-cluster N6), and one isolate clustered to
HPV 6 isolates from Germany and USA (sub-cluster N12). In addition,
one HPV 6 isolate was identical to isolate HPV 6ma (sub-cluster N7)
and one Slovenian HPV 6 isolate formed a unique (Slovenian) sub-
cluster N4.Fig. 1. Sequence variations of the L1 ORF (A), long-control region-LCR (B), and E6 ORF (C) of
indicated across the top vertically. Positions for which no variation was detected compared
Nucleotide substitutions, deletions, and insertions are marked with letters, Δ, and I, respecti
been amended by inclusion of a 94 bp segment (Heinzel et al., 1995). Ref-6a, Ref-6vc, 6-LCR-4
L41216) or HPV 6vc (GenBank acc. no. AF092932). The frequency (ƒ) indicates the number
compared to the reference HPV 6b sequences is provided. Insertions (I) and deletions (D): I
I4=T; D1=ATGTGTGTTGTATATATGT.Discussion
In this study, we describe HPV 6 prevaccination genomic diversity
over a span of 3798 nucleotides (app. half of the viral genome), among
the highest number of HPV 6 isolates to date. Our data set
complements and signiﬁcantly expands previous knowledge of HPV
6 genomic variants based on targeted analysis of L1, LCR, E6, and E2
genomic regions. In addition, this work is the ﬁrst investigation of
genetic variability of the HPV 6 E5 genomic region.
Sequence analysis of the six different genomic regions of 77
Slovenian HPV 6 isolates revealed a strong intergenomic co-variation
between the LCR region and L1, E6, E2, E5a, and E5b ORFs. Nucleotide
signatures speciﬁc for the prototypic and non-prototypic HPV 6
genomic variant lineages were clearly deﬁned for all sequences. These
regions showed, as a main feature, ﬁxed nucleotide variations in more
than one position. Similarly, all coding regions, except the L1 gene,
showed at least one ﬁxed amino acid location that was characteristic
for the non-prototypic HPV 6 variant group. In contrast to L1, LCR, E2,
and E5b genomic regions, E6 and E5a ORFs failed to supply sufﬁcient
information to distinguish HPV 6a and HPV 6vc genetic lineages. By
analyzing pooled L1, LCR, E6, E2, and E5 nucleotide data of an
individual isolate, a total of 36 different genomic variants were
identiﬁed among 77 HPV 6 isolates, of which 6 (12 isolates), 1 (one
isolate), and 29 (64 isolates) corresponded to HPV 6b, HPV 6a, and
HPV 6vc genetic lineages, respectively.
The L1 protein is the HPV major capsid protein and is the main
target of neutralizing antibody responses during natural infection.
Amino acid alterations of the L1 protein could potentially have
important biological consequences. A total of 15 L1 genomic variants
were identiﬁed in this study, of which three, represented by ten HPV 6
isolates from genital warts and three HPV 6 isolates from laryngeal
papillomas, had speciﬁc amino acid substitutions in L1 ORF. One L1
genomic variant had an amino acid substitution at position 7079
(E431Q), one at positions 7079 (E431Q) and 7121 (N445D), and one
variant had a speciﬁc amino acid substitution at position 7232 (P482S).
The single amino acid change E431Q that was found in 10/77 (14.3%)
HPV 6 isolates has been reported by Caparros-Wanderley et al. (1999)
as themost frequentmutation encountered amongHPV6 isolates from
genital warts. To our knowledge, the amino acid substitutions N445D
and P482S that were characteristic features of one and two HPV 6
isolates, respectively, are described for the ﬁrst time in this study.
Similar to E431Q, both mutations clustered in the C-terminal part of
the HPV 6 L1 protein, which ranks highly as a potential antibody-
reactive site andmight constitute a linear B-cell epitope on the surface
of the HPV 6 capsid (Jenison et al., 1989; Caparros-Wanderley et al.,
1999; Modis et al., 2002). However, the clinical signiﬁcance of these
mutations needs to be determined in further studies.
A series of previous reports have described HPV 6 genomic variants
that were characterized by sequence rearrangements, such as
insertions and deletions, in the LCR region. It was suggested that
these sequence alternations may affect the HPV 6 pathogenic proper-
ties by inﬂuencing the expression of viral genes. Surprisingly,
functional assays of the LCR region of different HPV 6 isolates from
benign andmalignant tumors, including HPV 6b, HPV 6a, and HPV 6vc,
revealed no major difference in the activities of their early promoters
that are responsible for the expression of E6 and E7 oncogenes
(Heinzel et al., 1995; Grassmann et al., 1996). However, speciﬁc77 Slovenian HPV 6 isolates. Genomic positions at which mutations were observed are
to the reference HPV 6b sequences (Ref-6b-O; GenBank acc. no. X00203) are shaded.
vely. The LCR sequence coded Ref-6b-H refers to the reference LCR sequence, which has
⁎, and 6-E6-4⁎ indicate nucleotide sequences identical to the HPV 6a (GenBank acc. no.
of isolates identiﬁed for each HPV 6 genomic variant. The change in amino acid (aa)
1=TATGTGTATATGTGTGTATA; I2=TACATTATTGTATA; I3=ATATGTTTATTGCCACTGCA;
278 B.J. Kocjan et al. / Virology 391 (2009) 274–283
Fig. 3. HPV 6 genomic variants found among 77 Slovenian HPV 6 isolates. The frequency (ƒ) indicates the number of isolates identiﬁed for each HPV 6 genomic variant.
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by inﬂuencing the expression of HPV 6 E2 and E1 replicating proteins,
as recently reported for HPV 16 (Hubert, 2005). In this study, a total of
15 HPV 6 LCR genomic variants were identiﬁed, all of which clearly
catalogued to the HPV 6b, HPV 6a, and HPV 6vc genetic lineages. A
single HPV 6a genomic variant was identical to the LCR sequence of
HPV 6a, while other variants differed from the LCR of HPV 6b or HPV
6vc by a maximum of seven mutations (Fig. 1). We have thus
demonstrated signiﬁcant conservation of the LCR genomic region
among all three HPV 6 genetic lineages.
The published genomic sequence of the prototype HPV 6b isolate
(GenBank acc. no. X00203) has been a matter of confusion, since it
misses a 94 bp segment in the LCR region that is present in the
majority of HPV 6 isolates characterized so far. In 1995, Heinzel et
al. recloned the LCR genomic region of the original HPV 6b isolate
and showed that this sequence is an intrinsic part of the HPV 6b
genome and was probably deleted during propagation of its clone in
bacteria (Heinzel et al., 1995). In line with this observation, we
detected this 94 bp “insert” in all analyzed HPV 6 isolates; in most
cases, it differed from the original insert by one or two pointFig. 2. Sequence variations of a 3′ half of the E2 ORF (nt 3289–3829) (A), E5a ORF (B), and
6-E5b-3⁎ indicate nucleotide sequences identical to the HPV 6a or HPV 6vc. See legend to
valine (V)] at codon 72 is for G (guanine); Cβ: aa change [tyrosine (Y) into histidine (H)] a
variants: Cα: the aa change, aspartate (D) into alanine (A) at codon 55 is for C; Gβ: the amutations (Fig. 4). In addition, the results of our study indicate that
a cloning artifact might occur also in the original HPV 6vc isolate
(GenBank acc. no. AF092932). Namely, all of the investigated HPV 6
isolates contained a 19 bp sequence insertion that is missing after
position 7367 in the published HPV 6vc genome sequence (Fig. 4).
This assumption is further supported by the fact that this part of the
HPV 6vc LCR coincides with the part of the HPV 6b LCR region in
which a 94 bp deletion occurred. In addition, the LCR sequences of
all HPV 6 isolates representing genomic variant 6-LCR-5 fully
matched the LCR sequence of the HPV 6vc isolate, except for the
missing part (Fig. 1).
Many important functions have been attributed to the high-risk
HPV E6/E7 proteins, including binding and degradation of p53,
interacting with retinoblastoma (Rb) proteins, facilitating the
proliferation of infected epithelial cells and, consequently, inducing
cellular transformation (Doorbar, 2006). In contrast, the physiolo-
gical roles of the HPV 6 E6/E7 proteins remain unclear (Oh et al.,
2004). Similarly, it is not clear whether genomic variants of HPV 6
E6/E7 genes encode viral proteins with altered pathogenic proper-
ties. Among 10 E6 genomic variants characterized in this study,E5b ORF (C) of 77 Slovenian HPV 6 isolates. 6-E2-3⁎, 6-E2-4⁎, 6-E5a-2⁎, 6-E5b-2⁎, and
Fig. 1 for details. Note to E5a genomic variants: Gα: the aa change [leucine (L) into
t codon 85 is for C (cytosine) at nt 4139 plus C at nt 4141, only. Note to E5b genomic
a change, aspartate (D) into glycine (G) at codon 55 is for G.
Fig. 4.Multiple alignment of a 5′ part of the LCR genomic region (nt 7340–7448) of the prototype HPV 6b (GenBank acc. no. X00203), HPV 6a (GenBank acc. no. L41216), and HPV
6vc (GenBank acc. no. AF092932) and HPV 6 isolates characterized in this study; for simplicity, only 18 representative HPV 6 isolates (LP22-LP129) are shown. The sequence coded
HPV-6b-H refers to the original HPV 6b LCR sequence, which has been amended by inclusion of a 94 bp segment (Heinzel et al., 1995). D1: a segment of 94 bp
(ATGTACTGTTATATGTATGTGTGTTGTATATATGTGTGTATATATGTGTCTGTGTGTATATGTATATGTATGTGTTGTGTATATATATGTGTGT); D2: a segment of 19 bp (ATGTGTGTTGTATATATGT).
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amino acid substitutions in the HPV 6 E6 gene; seven variants had
a substitution at position 251 (H50Q) and one variant had a speciﬁc
substitution at positions 156 (T19S) and 251 (H50Q). Since the
amino acid substitution H50Q was also found in the majority of HPV
6 isolates previously characterized (Grassmann et al., 1996), we
presume that it prevails in naturally occurring HPV 6 populations.
However, this amino acid exchange clustered outside current
functionally characterized domains of the HPV E6 protein (reviewed
in Grassmann et al., 1996); its meaning is therefore at present
unclear.
HPV E2 protein is a critical regulator of viral transcription and
replication. In a study by Kovelman et al. (1999) it has been shown
that E2 ORF is divergent between the three fully characterized HPV
6 genomes: HPV 6b, HPV 6a and HPV 6vc. In addition, this study
revealed several amino acid substitutions in the E2 protein that
were characteristic of HPV 6a and HPV 6vc genetic lineages. Using
the HPV 6b and HPV 6vc E2 proteins, very similar activities in
transcriptional activation and repression assays in primary human
keratinocytes were observed, suggesting that natural variants of the
HPV 6 E2 protein do not affect its regulatory function (Kovelman et
al., 1999). In this study, we analyzed the genetic variability of a 3′
part of the E2 gene that encodes for the E2 hinge and DNA-binding/
dimerisation domains. Among nine E2 genomic variants identiﬁed,
six (represented by 65 HPV 6 isolates) had amino acid sequences
identical to the E2 protein of HPV 6b, HPV 6a, or HPV 6vc isolates.
Additional novel amino acid substitutions were identiﬁed in one
prototypic (K351R, nt 3774) and in two HPV 6vc-related genomic
variants (G262A, nt 3507; H264Q, nt 3514 and Q273P, nt 3540). It
would, however, be of great interest to investigate further whether
identiﬁed natural variants of the HPV 6 E2 protein affect its key role
in controlling HPV 6 replication in conjunction with the E1 protein
and its variants.
The biological functions of the HPV E5 protein and its role in the
HPV replication cycle are not well understood. Documented
functions include transformation and stimulation of the prolifera-
tion of HPV-infected cells and induction of koilocytosis in conjunc-
tion with the HPV E6 proteins (Doorbar, 2006; Krawczyk et al.,
2008). In contrast to other alpha-PVs, which have one E5 ORF, HPV 6
possesses two E5 genes: E5a and E5b (Schwarz et al., 1983; Hofmann
et al., 1995; Kovelman et al., 1999). It has been shown previously that
both genes are actively transcribed in laryngeal papillomas (Ward
and Mounts, 1989), indicating that they may take part in productive
HPV 6 infection. We determined a total of 16 E5a genomic variants in
this study, of which eight (represented by 60 isolates) had an amino
acid sequence identical to the E5a protein of HPV 6b or HPV 6vcisolates. Novel amino acid substitutions detected at positions 3892
(E2D), 3912 (A9G), 3912 (A9G) and 4158 (Q91P), 4100 (L72V), and
4139/4141 (Y85H) in the E5a ORF constituted additional character-
istic features of an additional six HPV 6vc-related genomic variants.
Similarly, in the remaining two HPV 6vc genomic variants, a novel
HPV 6 E5a protein variant was identiﬁed; this protein differed from
the HPV 6vc E5a protein by a single amino acid substitution in codon
88 (Fig. 2, variants 6-E5a-11 and 6-E5a-12). In contrast to E5a, only
nine E5b genomic variants were identiﬁed, ﬁve of which, repre-
sented by 65 isolates, had amino acid sequences identical to the E5b
protein of HPV 6b, HPV 6a, or HPV 6vc isolates (Fig. 2). Novel amino
acid exchanges identiﬁed at positions 4267 (V37I), 4304 (N49T),
4322 (D55A) and 4342 (Y62H), and 4322 (D55G) in the E5b ORF
were additional characteristic features of the remaining four HPV
6vc-related genomic variants. Whether the reported amino acid
variations in the HPV 6 E5a and E5b ORFs affect the biological
functions of E5 proteins remains unknown.
The results of this study for the ﬁrst time allowed phylogenetic
comparison of HPV 6 genomic variants found worldwide (Heinzel
et al., 1995) with a relatively large number of HPV 6 isolates from
one geographically and ethnically closed cohort of patients (i.e.,
Slovenian patients). This LCR based phylogenetic comparison
showed that 76/77 (98.7%) Slovenian HPV 6 isolates were identical
to several phylogenetically diverse HPV 6 genomes identiﬁed
previously in other parts of the world. Thus, in contrast to HPV
16 and HPV 18, the existence of speciﬁc and geographically
restricted HPV 6 genomic variants seems highly unlikely.
In summary, the ﬁrst extensive work on the genomic diversity of
the HPV 6 genotype showed a substantial prevaccination genomic
diversity of this HPV genotype. A total of 36 different HPV 6 genomic
variants were identiﬁed in this study. Non-prototypic HPV 6
genomic variants belonging to the HPV 6vc genetic lineage were
found in the majority of genital warts and laryngeal papillomas
included in the study. The presence of serious sequence errors was
conﬁrmed and novel sequence errors were identiﬁed in sequence
repositories. We believe that our study will be helpful in future
epidemiological, functional, molecular assay development and
vaccination studies.
Materials and methods
Clinical samples
A total of 77 HPV 6 isolates were included in the study. Forty-ﬁve
isolates were obtained from the same number of male patients
suffering from exophytic genital warts on the glans of the penis, the
Fig. 5. Neighbor-joining algorithm based phylogenetic tree of HPV 6 LCR genomic variants from Slovenia (LP5-CAC116X), Brazil (AM6-1, B6-1, B6-4b, B6-5, B6-15, and B6-17),
Germany (G6-2b, G6-6, G6-8, G6-20, G6-42, and G6-78), India (IN6-2, IN6-3, and IN6-6), Italy (I6-1), Japan (J6-4, J6-6, J6-8, and J6-11), USA-NY (NY6-1, NY6-11, NY6-13, NY6-16, and
NY6-19), and Senegal (SN6-1, SN6-3, SN6-4b, SN6-6b, and SN6-11). Bootstrap values (%) above 50 are shown (1000 bootstrap replicates for each grouping of a tree).
281B.J. Kocjan et al. / Virology 391 (2009) 274–283coronal sulcus or the foreskin (Potočnik et al., 2007; Poljak et al.,
2009) and 32 isolates were obtained from 17 male and 15 female
patients suffering from laryngeal papillomas.
Ampliﬁcation of HPV 6 L1, LCR-E6, and E2-E5 genomic regions
The genomic diversity of all HPV 6 isolates was investigated within
the L1, LCR, E6, E2, E5a, and E5b regions of the HPV 6 genome. The
1796 bp fragment, which contained the complete L1 ORF (1503 bp)
was ampliﬁed by PCR using the primer pair HPV6-L1F (5′-TGTTTTCAT-TACAGGTTCTGGA-3′, nt 5700–5721) and HPV6-L1R (5′-TAAACACA-
CATACACATTACACAAA-3′, nt 7495–7471). The 1414–1430 bp fragment
containing the complete LCR genomic region (806–822 bp) and
complete E6 ORF (453 bp) was PCR ampliﬁed using the primer pair
HPV6-LCRF (5′-CTGCTGTTTCCAAAGCCTCT-3′, nt 7233–7252) and
HPV6-E6R (5′-CCACTTCGTCCACCTCATCT-3′, nt 650–631). The 1397 bp
fragment encompassing the 3′ half of E2 ORF and the entire E5a
(276 bp) and E5b (219 bp) ORFs was ampliﬁed by PCR using HPV6-E2F
(5′-GGACAMTGACWCCTGGGTAAAG-3′, nt 3142–3163) and HPV6-E5R
(5′-GTGTTGTGCTCCACCTTAG-3′, nt 4538–4520) primers. All primers
Table 1
List of primers used for sequencing the HPV 6 L1, LCR-E6, and E2-E5a-E5b PCR products.
Genomic
region
Primer Sequence (5′–3′) Genomic
positiona
L1 HPV6-L1S CGTAAACGTATTCCCTTATTTTTT (sense) 5761–5784
HPV6-FS2b CCCTGGACAGGATAAC (sense) 6190–6205
HPV6-L1S1 TTCTACGGAAGGAACAAATG (sense) 6522–6541
HPV6-L1S2 CAGACGTGCGATTTCCACTA (antisense) 6632–6613
HPV6-FS5b CCACACGCAGTACC (sense) 6783–6796
LCR-E6 HPV6-LCRSc AATCCTATATATTTTGTGCCAGGT (sense) 7703–7726
HPV6-LCRS1c TTGGCAGGATATGATGCACT (antisense) 7774–7755
HPV6-LCRS2 TGGTCTATGGTCGTTGCAGA (antisense) 145–126
HPV6-E6S ATAGGAGGGACCGAAAACG (sense) 26–44
E2–E5 HPV6-E2S AATGTGCTGGTTGTTCCTGC (antisense) 3933–3914
HPV6-E5S GTGAGGAACAAAGGCAACAGT (sense) 3738–3758
a Nucleotide positions of primers were compared to the prototype HPV 6 genome
(GenBank acc. no. X00203).
b Primers reported by Caparros-Wanderley et al. (1999).
c Nucleotide positions of these primers were compared to the corrected LCR
sequence of the prototype HPV 6 (Heinzel et al., 1995).
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the prototype HPV 6b isolate (GenBank acc. no. X00203), and HPV 6a
(GenBank acc. no. L41216) and HPV 6vc (GenBank acc. no. AF092932)
isolates using Primer3 (http://frodo.wi.mit.edu/) and Netprimer
(http://www.premierbiosoft.com) programs. The corrected LCR
sequence of prototype HPV 6b (Heinzel et al., 1995) was used for
designing and genomic position numbering of primers located in the
HPV 6 LCR genomic region.
All PCR reactions were performed in 0.2 ml reaction tubes, each
containing up to 200 ng of template DNA, 25 μl of High Fidelity PCR
Master (Roche Diagnostics, Manheim, Germany), 300 nm of each of
the “gene”-speciﬁc primers and water up to 50 μl. The cycling
conditions used were 2 min at 94 °C, and 10 cycles of 10 s at 94 °C,
70 s at 55 °C and 1 min at 72 °C. This was followed by additional 25
cycles of 15 s at 94 °C, 30 s at 55 °C and 1 min at 72 °C (the extension
step increased by 5 s for each successive cycle). The ﬁnal extension
step was performed at 72 °C for 7 min and the reaction mixtures
were cooled to 4 °C. All PCR ampliﬁcations were carried out on the
GeneAmp® PCR instrument type 9700 (PE Applied Biosystems,
Foster City, USA).
Sequencing and identiﬁcation of HPV 6 genomic variants
The PCR products were analyzed on ready-to-use PCR CheckIT
Wide Mini S-2x25 gels (Elchrom Scientiﬁc, Zurich, Switzerland)
using a 500 bp DNA ladder (Roche Diagnostics) and puriﬁed with a
QIAquick PCR puriﬁcation kit (Qiagen, Hilden, Germany). Concen-
trations of puriﬁed amplicons were estimated on a 0.8% agarose gel
(A9539-Agarose, Sigma-Aldrich, St. Louis, USA) using a High DNA
Mass Ladder (Invitrogen, Carlsbad, USA) and set to 50 ng/μl.
Sequencing of PCR products was performed at Macrogen, Ltd.
(Seoul, Korea) with the same primers as those used for PCR.
Additional sequencing primers that were also used are given in
Table 1. HPV 6 L1, E6, E2, E5a, and E5b genomic variants were
identiﬁed with the BioEdit Sequence Alignment Editor v7.0.5.3
(North Carolina State University, Raleigh, USA), using the genome of
prototype HPV 6b isolate (GenBank acc. no. X00203) as a standard
for comparisons and nucleotide position numbering. The corrected
LCR sequence of prototype HPV 6b (Heinzel et al., 1995) was used
for determination of HPV 6 LCR genomic variants.
Phylogenetic analyses of HPV 6 variants were based on multiple
alignment of LCR sequences between HPV 6 genomic positions 7676
and 7939 (a segment of 264–268 bp) and performed using the Phylip
program package (v3.65), as described previously (Heinzel et al.,
1995); a neighbor-joining (NJ) method was used to construct a
phylogenetic tree, which was visualized with the Treeview program
(v1.6.6) of the University of Glasgow.Nucleotide-sequence accession numbers
The HPV 6 nucleotide sequence data reported in this paper are
deposited in the DDBJ, EMBL and GenBank databases under the
following accession numbers: L1 sequences (FM876121–FM876165,
FM897134–FM897165), LCR sequences (FM876166–FM876210,
FM897166–FM897197), E6 sequences (FM875941–FM875985,
FM897006–FM897037), E2 sequences (FM875986–FM876030,
FM897038–FM897069), E5a sequences (FM876031–FM876075,
FM897070–FM897101), and E5b sequences (FM876076–FM876120,
FM897102–FM897133).
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